April 25, 2021
4 min watch
Save
VIDEO: Routine lab monitoring not necessary with long-term dupilumab for AD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video from AAD VMX 2021, Andrew Blauvelt, MD, MBA, discusses his presentation on the necessity of laboratory testing for adult patients on long-term dupilumab treatment for moderate to severe atopic dermatitis.